Virtual Library
Start Your Search
E. Ozbilek
Author of
-
+
P3.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC (ID 214)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Locoregional Disease – NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.03-036 - PET for Prognostic Assessment in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy (ID 1197)
09:30 - 09:30 | Author(s): E. Ozbilek
- Abstract
Background:
Concurrent chemoradiotherapy is the standard of care for locally advanced, unresectable non-small cell lung carcinoma(NSCLC). The study purpose was to assess the prognostic value of maximum standardized uptake values (SUV max) from FDG PET/CT for stage III NSCLC.
Methods:
This study included 61 patients with unresectable stage III NSCLC treated with concurrent thoracic radiotherapy (63Gy) given with cisplatin and etoposide. 18F-FDG PET/CT scans were obtained from all patients within 45 days before treatment. The prognostic value of SUVmax of the primary tumors were analyzed with univariate Cox regression. Survival was estimated using the Kaplan–Meier method
Results:
The median age of the patients was 56 years (range 40–71). The median follow-up time was 20 months (range 1.4–81 months). The median SUVmax of the tumor (15.0) was decided as the cutoff value, and the impact of the SUVmax on survival was statistically evaluated according to this cutoff value. There was no a statistically significant difference in overall survival (OS) between the low (≤15) and high (>15) SUVmax groups (p = 0.006) upon univariate analysis (p=0.403).
Conclusion:
SUV max of the primary tumor did not predicted overall survival in patients with unresectable stage III NSCLC treated with concurrent chemotherapy and radiotherapy
